HSKA earnings

Full Year Sales $257.3 Million, Full Year Gross Margin Up 150 Basis Points to 43.2% Full Year North America Lab Consumables Sales Up 8.7%, Total Active Subscriptions Up 18% LOVELAND, Colo., Feb. 28, 2023 /PRNewswire/ -- Heska Corporation (NASDAQ:HSKA, ", Heska", or ", Company", ))), a leading global provider of advanced veterinary diagnostic and specialty products, reported financial results in two segments (North America and International) for its fourth quarter and full year ended December 31, 2022. Fourth Quarter and Full Year 2022 and Year Over Year ("YOY") Metrics $ in mi

LOVELAND, Colo., Feb. 8, 2023 /PRNewswire/ -- Heska Corporation (NASDAQ:HSKA, ", Heska", or the ", Company", ))), a leading global provider of advanced veterinary diagnostic and specialty solutions, will report its fourth quarter and full year 2022 financial performance in a press release before the market opens on Tuesday, February 28, 2023. The Company will also host an earnings call at 9 a.m. MT / 11 a.m. ET to discuss the results. To access the conference call: From within the United States, please dial 1-877-41-6152From outside of the United States, please dial 1-201-389-

LOVELAND, Colo., Jan. 3, 2023 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA; "Heska" or the "Company"), a leading global provider of advanced veterinary diagnostic and specialty products and solutions, today announced the completion of acquisition of 100% of the shares of MBio Diagnostics, Inc. d/b/a LightDeck Diagnostics ("LightDeck"), a pioneer in planar waveguide fluorescence immunoassay diagnostics with strong manufacturing capabilities and research and development expertise (the "Acquisition").  The Acquisition, which was first announced on September 12, 2022, represent

North America Point of Care Lab Consumables up 11.4%, Consolidated Gross Margin up 180 bps LOVELAND, Colo., Nov. 8, 2022 /PRNewswire/ -- Heska Corporation (NASDAQ:HSKA, ", Heska", or the ", Company", ))), a leading global provider of advanced veterinary diagnostic and specialty solutions, reported financial results in two segments (North America and International) for its third quarter ended September 30, 2022. In this release, Point of Care is "POC", Pharmaceuticals, Vaccines and Diagnostics is "PVD", Other Vaccines and Pharmaceuticals is "OVP", and basis points is "bps". Thi

LOVELAND, Colo., Oct. 18, 2022  /PRNewswire/ -- Heska Corporation (NASDAQ:HSKA, ", Heska", or the ", Company", ))), a leading global provider of advanced veterinary diagnostic and specialty solutions, will report its third quarter 2022 financial performance in a press release before the market opens on Tuesday, November 8, 2022. The Company will also host an earnings call at 9 a.m. MT / 11 a.m. ET to discuss the results. To access the conference call: From within the United States, please dial 1-800-239-9838From outside of the United States, please dial 1-323-794-2551Reference

LOVELAND, Colo., Sept. 12, 2022 /PRNewswire/ -- Heska Corporation (NASDAQ:HSKA, ", Heska", or the ", Company", ))), a leading global provider of advanced veterinary diagnostic and specialty solutions, announced today that the Company has entered a definitive agreement to acquire 100% of the share capital of MBio Diagnostics, Inc. d/b/a LightDeck Diagnostics ("LightDeck"), a pioneer in innovative planar waveguide fluorescence immunoassay diagnostics with strong manufacturing and specialized production capabilities (the "Acquisition").   Founded in 2009 and headquartered in Boul

LOVELAND, Colo., Aug. 8, 2022 /PRNewswire/ -- Heska Corporation (NASDAQ:HSKA, ", Heska", or the ", Company", ))), a leading global provider of advanced veterinary diagnostic and specialty solutions, reported financial results in two segments (North America and International) for its second quarter ended June 30, 2022. In this release, Point of Care is "POC", Pharmaceuticals, Vaccines and Diagnostics is "PVD", Other Vaccines and Pharmaceuticals is "OVP", and basis points is "bps".   Second Quarter 2022 and Year Over Year ("YOY") Metrics $ in millions except Earnings Per Share (

LOVELAND, Colo., July 20, 2022 /PRNewswire/ -- Heska Corporation (NASDAQ:HSKA, ", Heska", or the ", Company", ))), a leading global provider of advanced veterinary diagnostic and specialty solutions, will report its second quarter 2022 financial performance in a press release before the market opens on Monday, August 8, 2022. The Company will also host an earnings call at 9 a.m. MT / 11 a.m. ET to discuss the results. To access the conference call:    From within the United States, please dial 1-800-289-0720    From outside of the United States, please dial 1-323-701-0160    R

Quarterly Revenue Up 7% (10% in Constant Currency), Gross Margin Up 290 bps North America POC Lab Consumables Up 10%, Full Year Outlook Reiterated LOVELAND, Colo., May 9, 2022 /PRNewswire/ -- Heska Corporation (NASDAQ:HSKA, ", Heska", or the ", Company", ))), a leading global provider of advanced veterinary diagnostic and specialty solutions, reported financial results in two segments (North America and International) for its first quarter ended March 31, 2022. First Quarter 2022 and Year Over Year ("YOY") Metrics $ in millions except Earnings Per Share ("EPS") Q1 ($) Q1 (%) Y

LOVELAND, Colo., April 18, 2022 /PRNewswire/ -- Heska Corporation (NASDAQ:HSKA, ", Heska", or the ", Company", ))), a leading global provider of advanced veterinary diagnostic and specialty solutions, will report its first quarter 2022 financial performance in a press release before the market opens on Monday, May 9, 2022. The Company will also host an earnings call at 9 a.m. MT / 11 a.m. ET to discuss the results. To access the conference call:    From within the United States, please dial 1-800-239-9838    From outside of the United States, please dial 1-323-794-2551    Refe

LOVELAND, Colo., Feb. 28, 2022 /PRNewswire/ -- Heska Corporation (NASDAQ:HSKA, ", Heska", or ", Company", ))), a leading global provider of advanced veterinary diagnostic and specialty products, reported financial results in two segments (North America and International) for its fourth quarter and full year ended December 31, 2021. In this release, Point of Care is "POC", Pharmaceuticals, Vaccines and Diagnostics is "PVD", Other Vaccines and Pharmaceuticals is "OVP", scil animal care company GmbH is "scil", and basis points is "bps". Report Highlights Full year active subscrip

LOVELAND, Colo., Jan. 31, 2022 /PRNewswire/ -- Heska Corporation (NASDAQ:HSKA, ", Heska", or the ", Company", ))), a leading global provider of advanced veterinary diagnostic and specialty products and solutions, will report its fourth quarter and full year 2021 financial performance in a press release before the market opens on Monday, February 28, 2022. The Company will also host an earnings call at 9 a.m. MT / 11 a.m. ET to discuss the results. To access the conference call:From within the United States, please dial 1-800-239-9838From outside of the United States, please di

LOVELAND, Colo., Jan. 3, 2022 /PRNewswire/ -- Heska Corporation (NASDAQ:HSKA, ", Heska", or the ", Company", ))), a leading global provider of advanced veterinary diagnostic and specialty products and solutions, today announced the completion of the acquisition of VetZ GmbH ("VetZ"), a European trailblazer in veterinary practice information management software solutions ("PIMS") (the "Acquisition"). The Acquisition, which was first announced on November 2, 2021, represents a key milestone in the Company's strategic plan. Headquartered in Germany, VetZ has been a leader since its founding in 1997, providing powerful, easy-to-use and fully integrated software solutions for better workflow, com

LOVELAND, Colo., Nov. 4, 2021 /PRNewswire/ -- Heska Corporation (NASDAQ:HSKA, ", Heska", or ", Company", ))), a leading provider of advanced veterinary diagnostic and specialty products, reported financial results in two segments (North America and International) for its third quarter ended September 30, 2021. In this release, Point of Care is "POC", Pharmaceuticals, Vaccines and Diagnostics is "PVD", Other Vaccines and Pharmaceuticals is "OVP", contract subscription value is "CSV", practice information management software is "PIMS", Biotech Laboratories U.S.A. LLC is "Biotech", BiEsseA Laboratorio Veterinario Srl is "BiEsseA", Lacuna Diagnostics, Inc. is "Lacuna", and scil animal care compa

LOVELAND, Colo., Nov. 2, 2021 /PRNewswire/ -- Heska Corporation (NASDAQ:HSKA, ", Heska", or the ", Company", ))), a leading global provider of advanced veterinary diagnostic and specialty products, announced today that the Company has entered a definitive agreement (the "Agreement") to acquire 100% of VetZ GmbH ("VetZ"), a European leader in veterinary practice information management software solutions ("PIMS") (such transaction, the "Acquisition"). Founded in 1997 and headquartered in Isernhagen, Germany, VetZ has created powerful, easy-to-use and fully integrated software so

LOVELAND, Colo., Oct. 12, 2021 /PRNewswire/ -- Heska Corporation (NASDAQ:HSKA, ", Heska", or the ", Company", ))), a leading provider of advanced veterinary diagnostic and specialty products, will report its third quarter 2021 financial performance in a press release before the market opens on Thursday, November 4, 2021. The Company will also host an earnings call at 9 a.m. MT / 11 a.m. ET to discuss the results. To access the conference call:    From within the United States, please dial 1-888-394-8218    From outside of the United States, please dial 1-323-701-0225    Reference Conference ID: 2365183 The earnings call will be webcast live from the Company's investor relations website at

LOVELAND, Colo., Aug. 3, 2021 /PRNewswire/ -- Heska Corporation (NASDAQ:HSKA, ", Heska", or ", Company", ))), a leading provider of advanced veterinary diagnostic and specialty products, reported financial results in two segments (North America and International) for its second quarter ended June 30, 2021. Point of Care is "POC" and scil animal care company GmbH is "scil" in this release. Second Quarter 2021 and Year Over Year ("YOY") Metrics $ in millions except Earnings Per Share ("EPS") Q2 ($) Q2 (%) YOY Consolidated Revenue $64.9 42.0% North America Revenue $40.5 39.9% Int